2/2 Join us in Lund 22-23 Oct to be a part of this exciting event and connect with leading researchers in immune engineering. Registration closes 12 Oct: immunitybydesign.se

1/2 Less than one week left to register for the Immunity by Design: In VivoImmune Cell Engineering Conference!

2/2 Don’t miss out on this opportunity to be at the forefront of immune engineering and immunotherapy. Join us in Lund, 22-23 Oct 2026! Submit your abstract here: immunitybydesign.se

1/2 Today is the last day to submit your abstract for the Immunity by Design: In Vivo Immune Cell Engineering Conference!

2/2 With extensive experience in academic and biotech settings, Rachel Nimmo focuses on immunotherapy for cancer and autoimmune diseases, including in vivo CAR T cell therapy. Find out more in Lund 22-23 Oct! Registration and abstract submission: immunitybydesign.se

1/2 We’re excited to announce our Industry Session keynote for the Immunity by Design: In Vivo Immune Cell Engineering Conference! Rachael Nimmo (former director of the Cell Technology Group at OXB).

2/2 How do immune cell engineering strategies progress from the lab to the clinic? Join the discussion on biotech creation, product development, and clinical manufacturing. The conference will be held in Lund 22–23 Oct. Register and submit your abstract: immunitybydesign.se

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conference presents the Industry Session, featuring Lorenz Mayr (BioMedTech Consulting) Cristiana Pires (@AsgardThx ), and Sara Mangsbo (@uppsalauni).

2/2 Enjoy the rest of the summer but make sure to secure your spot within the immune cell engineering network. Join us in Lund, 22-23 Oct 2026. Submit your abstract here: immunitybydesign.se

1/2 Good news! ✨ The abstract submission deadline for the Immunity by Design: In Vivo Immune Cell Engineering Conference has been extended until 1 Sept 2026.

2/2 From drug development to nanotechnology and non-viral delivery, how can we maximize disease targeting and therapeutic efficacy? Join us in Lund 22–23 Oct for this interesting session! Register and submit your abstract: immunitybydesign.se

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conferenceintroduces Session 3: Delivery Technologies & Translation, joining Alexandra Teleki (Uppsala University), Jai Prakash (Radboud University Medical Centre), and Samir El Andaloussi (Karolinska Institutet).

15) 🙏🏻 A big thank you to all the funding agencies for making this possible: @ERC_Research, @HorizonEU, @Cancerfonden, @Vetenskapsradet, @fct_pt, #NextgenerationEU, @Lunduniversity, @Lund_Stem, LUCC, @CNC_UC, and Region Skåne.

14) 👥 We are grateful to our collaborators Darja Schaefer, Carol Geukens, and @AsgardThx for their incredible contributions!

13) 📖 This study was only possible because of the great effort from Pereira Lab members Nejc Arh, Ilia Kurochkin, and Beatriz Lourenço Vaz

12) Together, our work identifies miRNA isoform diversity as a programmable layer of cell fate control and opens new opportunities for cancer immunotherapy.

11) Our takeaway: - miR-124 promotes early chromatin remodeling - miR-142 reinforces cDC1 identity and function - miR-142 isomiRs cooperate during cDC1 reprogramming - miR-142 enhances anti-tumor immunity of in vivo cDC1 reprogramming - mRNAs+miRNAs enable non-viral reprogramming

10) Combining the delivery of PIB mRNAs with miRNA mimics showed cooperative effects and initiated non-viral cDC1 reprogramming.

9) Importantly, miR-142 improved cancer cell reprogramming and enhanced anti-tumor immunity in vivo, leading to reduced tumor growth and increased survival rates.

8) Functionally, miR-142-enhanced cells produced more IFN-λ1, a cytokine strongly associated with cDC1 biology and anti-tumor immunity. We further identified TGFBR1 as a miR-142-regulated barrier to cDC1 reprogramming.